|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Immunomedics
gptkb:Kite_Pharma
gptkb:Pharmasset
|
|
gptkbp:CEO
|
gptkb:Daniel_O’Day
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
gptkb:COVID-19
gptkb:Hepatitis_B
gptkb:Hepatitis_C
HIV/AIDS treatment
Antiviral drugs
|
|
gptkbp:founded
|
1987
|
|
gptkbp:founder
|
gptkb:Michael_L._Riordan
|
|
gptkbp:fullName
|
gptkb:Gilead_Sciences,_Inc.
|
|
gptkbp:headquartersLocation
|
gptkb:Foster_City,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilead
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:keyPerson
|
gptkb:Andrew_Dickinson
gptkb:Brett_Pletcher
gptkb:Cristina_Durán
gptkb:Diana_Brainard
gptkb:Flavius_Martin
gptkb:Jacquie_Ross
gptkb:Javier_Rodriguez
gptkb:Johanna_Mercier
gptkb:Linda_Higgins
gptkb:Mark_Genovese
gptkb:Merdad_Parsey
gptkb:Daniel_O’Day
|
|
gptkbp:marketCap
|
~$90 billion (2023)
|
|
gptkbp:netIncome
|
$4.6 billion (2022)
|
|
gptkbp:notableProduct
|
gptkb:Remdesivir_(COVID-19_treatment)
gptkb:Truvada_(HIV_PrEP)
gptkb:Veklury_(COVID-19)
Biktarvy (HIV)
Harvoni (Hepatitis C)
Sovaldi (Hepatitis C)
|
|
gptkbp:numberOfEmployees
|
~17,000 (2023)
|
|
gptkbp:parentCompany
|
nan
|
|
gptkbp:products
|
gptkb:Biktarvy
gptkb:Harvoni
gptkb:Remdesivir
gptkb:Sovaldi
gptkb:Truvada
gptkb:Veklury
|
|
gptkbp:publiclyTraded
|
Yes
|
|
gptkbp:revenue
|
$27.3 billion (2022)
|
|
gptkbp:stockExchange
|
gptkb:S&P_500
|
|
gptkbp:stockSymbol
|
gptkb:GILD
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:GILD
|
|
gptkbp:website
|
https://www.gilead.com/
|
|
gptkbp:bfsParent
|
gptkb:Marilynne_Robinson
gptkb:The_Handmaid's_Tale
|
|
gptkbp:bfsLayer
|
4
|